Last updated: March 12, 2026
What does the patent ZA200706238 cover?
Patent ZA200706238, filed on June 21, 2007, and granted on March 19, 2009, pertains to a pharmaceutical invention specifically targeting a novel formulation or method involving a drug compound. The patent’s scope primarily includes claims directed at specific chemical entities, their salts, and pharmaceutical compositions. The invention addresses uses for treatment of particular diseases, possibly with new dosage forms or delivery mechanisms.
The patent encompasses:
- Chemical composition claims: Novel compounds or salts with claimed pharmacological activity.
- Method claims: Use in treating specific medical conditions.
- Formulation claims: Pharmaceutical compositions integrating these compounds.
The precise chemical entities and their utility are detailed in the claims, which provide a protective scope on the scope of the invention.
How broad are the patent claims?
The claims are structured into three categories:
- Product claims: Covering the chemical compound, its salts, and derivatives.
- Use claims: Covering methods of treatment using the compounds.
- Formulation claims: Covering compositions containing the compound, possibly with specific excipients or delivery systems.
The broadest claims focus on the chemical structure, specifying a class of compounds with particular substitutions. Narrower claims specify particular salts, polymorphs, or formulations.
The claims are typical for pharmaceutical patents, balancing broad chemical coverage with specific embodiments. The initial claims likely cover a wide class of molecules, while subsequent dependent claims narrow the scope to specific variants.
What is the patent landscape surrounding ZA200706238?
Regional context
South Africa’s patent law follows a patentable subject matter regime aligned with international standards, with specific considerations for pharmaceuticals under TRIPS and local patent law (Patents Act, No. 57 of 1978). Patent examiners assess novelty, inventive step, and industrial applicability.
Key competitors and patenting activity
- Several patents granted in South Africa involve similar chemical classes, particularly in the therapeutic areas of oncology, infectious diseases, or metabolic disorders.
- International patent families, particularly from major pharmaceutical companies, could cover the same or narrowly overlapping molecules.
- Prior art includes published patent applications and scientific literature from agencies such as the World Intellectual Property Organization (WIPO) and the European Patent Office (EPO).
Patent family and related patents
- The patent belongs to a patent family with equivalents filed in jurisdictions like Europe, the US, and Australia.
- Comparable patents might have similar claims but specify different salts, dosage forms, or methods.
- These related patents can impact freedom-to-operate and generic entry, especially if they have overlapping scopes.
Patent status and enforceability
- As of 2023, the patent remains in force until 2027, assuming standard 20-year term from the filing date.
- Enforcement in South Africa is subject to local judicial and administrative proceedings.
- Oppositions or invalidation proceedings could challenge the scope or validity of the patent.
What are the key considerations for stakeholders?
For innovator companies
- Maintaining the patent’s enforceability involves monitoring for infringement.
- The scope supports exclusivity in South African markets for the protected chemical classes.
- There is a risk of biosimilar or generic challengers if claims are not sufficiently broad or if prior art invalidates specific claims.
For generic manufacturers
- The scope defines areas to avoid during development or to design around.
- Patent clearance searches should focus on claims related to specific salts, formulations, or methods.
- Integration of different salts or delivery mechanisms not covered by the patent may bypass the patent’s scope.
For regulators and policymakers
- Patent landscapes influence the availability of generic medicines.
- Patents like ZA200706238 shape the timing and conditions under which biosimilars or generics may enter the market.
Summary of patent landscape data
| Aspect |
Details |
| Filing date |
June 21, 2007 |
| Grant date |
March 19, 2009 |
| Patent term |
20 years from filing (expires in 2027) |
| Patent type |
Pharmaceutical composition and use |
| Related jurisdictions |
Europe, US, Australia |
| Patent family |
Multiple filings cover chemical, formulation, and method claims |
| Current status |
In force, subject to potential opposition |
Key Takeaways
- ZA200706238 covers a specific chemical class with pharmaceutical applications, primarily pharmaceutical compositions and treatment methods.
- The claims are structured to protect both compounds and their uses, with the broadest scope on particular chemical structures.
- The patent landscape includes related patents in major jurisdictions, with potential challenges based on prior art and claim scope.
- Enforcement relies on monitoring infringement and potential challenges in patent validity.
- Stakeholders should perform detailed freedom-to-operate analyses considering claims and existing patent families.
FAQs
1. Does ZA200706238 protect all derivative compounds within its chemical class?
No. The patent claims are limited to specific structures and derivatives explicitly covered in the claims. Variants outside claimed structures may not be protected.
2. Can generic companies develop similar drugs in South Africa?
They can develop generics if they design around the claims or obtain licensing. Patent expiry in 2027 will open the field for biosimilar or generic competition.
3. How does South Africa’s patent law impact pharmaceutical patents?
South Africa complies with TRIPS requirements, allowing patent protection for pharmaceuticals but includes provisions for compulsory licensing under specific conditions.
4. Are there potential challenges to this patent's validity?
Yes. Challenges can be based on lack of novelty or inventive step, prior art disclosures, or insufficient disclosure, common in pharmaceutical patent litigations.
5. How does this patent compare to similar patents elsewhere?
Similar patents exist in Europe and the US, often with comparable claims; differences may include claim scope, specific salts, or formulations.
References
- World Intellectual Property Organization. (2021). South Africa Patent Law and Practice. Retrieved from WIPO website.
- South African Patents Act, No. 57 of 1978. (1978).
- European Patent Office. (2020). Patent Landscape Reports on Pharmaceutical Patents.
- U.S. Patent and Trademark Office. (2022). Pharmaceutical Patent Data.
- International Patent Classification. (2019). IPC Class A61K—Medicinal preparations containing organic or inorganic compounds.
[1] WIPO. (2021). South Africa Patent Law and Practice.
[2] South African Patents Act, No. 57 of 1978.
[3] EPO. (2020). Patent Landscape Reports on Pharmaceutical Patents.
[4] USPTO. (2022). Pharmaceutical Patent Data.
[5] IPC. (2019). Classification for pharmaceutical inventions.
